Global COVID-19 Vaccine Stock Dominated by AstraZeneca

COVID-19 vaccination is crucial for building community immunity (herd immunity) against the Corona virus.

However, according to Our World Data, as of today, only 61% of the global population has received at least one dose of the COVID-19 vaccine (as of February 11, 2022).

In Indonesia itself, only about 48% of the population has received a complete dose of the COVID-19 vaccine, with an additional 19% having received the first dose (as of February 11, 2022).

Therefore, the world still needs billions more doses of the COVID-19 vaccine to fully protect the global population and enable countries to quickly recover from the crisis caused by the pandemic.

Global COVID-19 Vaccine Production Continues to Increase

Several COVID-19 vaccine-producing countries continue to ramp up production to meet global demand.

According to WTO-IMF COVID-19 Vaccine Trade Tracker data, by the end of 2021, approximately 11.5 billion doses of vaccine had been produced worldwide.

Breakdown of Global COVID-19 Vaccine Stock by Type as of December 31, 2021:

1. AstraZeneca: 2.711 billion doses
2. Sinovac: 2.593 billion doses
3. Sinopharm: 2.359 billion doses
4. Pfizer: 2.213 billion doses
5. Moderna: 744 million doses
6. J&J: 552 million doses
7. Sputnik V: 275 million doses
8. Others: 59 million doses

This entire stock is used both for domestic needs of the producers and for export to other countries that are not yet able to independently produce vaccines.

(Also read: COVID-19 Vaccination Produces 144,000 Tons of Medical Waste, What Forms Does It Take?)